Patents by Inventor Pasquale Forgione
Pasquale Forgione has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11034702Abstract: The present disclosure relates to fused N-arylsulfonamidyl-thienoisoquinoline compounds, derivatives and pharmaceutical compositions thereof, and methods and uses in inhibiting cancer cell growth, along with a supplemental anti-cancer agent. Centrosome targeting and microtubule depolymerisation are attractive in designing the present chemotherapeutic compounds. The various diseases and conditions treated include various types of cell cancers, and in vitro inhibition.Type: GrantFiled: December 6, 2017Date of Patent: June 15, 2021Assignee: VALORBEC, SOCIÉTÉ EN COMMANDITEInventors: Pasquale Forgione, Alisa Julienne Piekny, Dilan Boodhai Jaunky, Fei Chen, Jiang Tian Liu
-
Publication number: 20200276181Abstract: The present disclosure relates to compounds, methods and uses thereof for targeting tubulin, ch-TOG, Aurora A kinase, TPX2, Cdk5rap2 and/or ASPM and for the treatment of cancer in a subject. For example, the compounds can comprise compounds of Formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof. A, Z, RA, RB, R1, R2, R3, R4 and R5 can have different values.Type: ApplicationFiled: November 15, 2018Publication date: September 3, 2020Applicant: VALORBEC, SECInventors: Pasquale FORGIONE, Alisa Julienne PIEKNY, Kevin LAROCQUE, Dilan Boodhai JAUNKY, Fei CHEN, Jiang Tian LIU
-
Publication number: 20200024284Abstract: The present disclosure relates to fused N-arylsulfonamidyl-thienoisoquinoline compounds, derivatives and pharmaceutical compositions thereof, and methods and uses in inhibiting cancer cell growth, along with a supplemental anti-cancer agent. Centrosome targeting and microtubule depolymerisation are attractive in designing the present chemotherapeutic compounds. The various diseases and conditions treated include various types of cell cancers, and in vitro inhibition.Type: ApplicationFiled: December 6, 2017Publication date: January 23, 2020Inventors: Pasquale FORGIONE, Alisa Julienne PIEKNY, Dilan Boodhai JAUNKY, Fei CHEN, Jiang Tian LIU
-
Patent number: 8912182Abstract: Compounds of formula I: wherein X, R2, R3, R3a, R3b, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.Type: GrantFiled: August 15, 2013Date of Patent: December 16, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Pierre L. Beaulieu, Pasquale Forgione, Alexandre Gagnon, Cedrickx Godbout, Marc-Andre Joly, Montse Llinas-Brunet, Julie Naud, Martin Poirier, Jean Rancourt
-
Publication number: 20130331391Abstract: Compounds of formula I: wherein X, R2, R3, R3a, R3b, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.Type: ApplicationFiled: August 15, 2013Publication date: December 12, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Pierre L. BEAULIEU, Pasquale FORGIONE, Alexandre GAGNON, Cedrickx GODBOUT, Marc-Andre JOLY, Montse LLINAS-BRUNET, Julie NAUD, Martin POIRIER, Jean RANCOURT
-
Patent number: 8541402Abstract: Compounds of formula I: wherein X, R2, R3, R3a, R3b, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.Type: GrantFiled: May 3, 2012Date of Patent: September 24, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Pierre L. Beaulieu, Pasquale Forgione, Alexandre Gagnon, Cedrickx Godbout, Marc-Andre Joly, Montse Llinas-Brunet, Julie Naud, Martin Poirier, Jean Rancourt
-
Patent number: 8476257Abstract: Compounds of formula I: wherein X, R2, R3, R3a, R3b, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.Type: GrantFiled: December 3, 2008Date of Patent: July 2, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Pierre L. Beaulieu, Pasquale Forgione, Alexandre Gagnon, Cedrickx Godbout, Marc-Andre Joly, Montse Llinas-Brunet, Julie Naud, Martin Poirier, Jean Rancourt
-
Publication number: 20120269769Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: July 3, 2012Publication date: October 25, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Josee BORDELEAU, Pasquale FORGIONE, Elise GHIRO, Vida GORYS, Nathalie GOUDREAU, Sylvie GOULET, Teddy HALMOS, Jean RANCOURT
-
Publication number: 20120214783Abstract: Compounds of formula I: wherein X, R2, R3, R3a, R3b, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.Type: ApplicationFiled: May 3, 2012Publication date: August 23, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Pierre L. BEAULIEU, Pasquale FORGIONE, Alexandre GAGNON, Cedrickx GODBOUT, Marc-Andre JOLY, Montse LLINAS-BRUNET, Julie NAUD, Martin POIRIER, Jean RANCOURT
-
Publication number: 20120101091Abstract: The present application provides compounds of formula I wherein X, Y, R2, n, R5 and R6 are defined herein, useful as inhibitors of the hepatitis C virus NS5B polymerase The present application also provides pharmaceutical compositions containing said compounds, methods of using said compounds as pharmaceuticals alone or with other antiviral agent in the treatment of a hepatitis C viral infection in a mammal having or at risk of having the infection.Type: ApplicationFiled: October 1, 2009Publication date: April 26, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Pierre Beaulieu, Pierre Bonneau, René Coulombe, Pasquale Forgione, James Gillard, Araz Jakalian, Jean Rancourt
-
Publication number: 20120034187Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: October 21, 2011Publication date: February 9, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Josee BORDELEAU, Pasquale FORGIONE, Elise GHIRO, Vida GORYS, Nathalie GOUDREAU, Sylvie GOULET, Teddy HALMOS, Jean RANCOURT
-
Patent number: 8067438Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: GrantFiled: April 1, 2011Date of Patent: November 29, 2011Assignee: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Douglas Bailey, Punit R. Bhardwaj, Josee Bordeleau, Pasquale Forgione, Elise Ghiro, Vida J. Gorys, Nathalie Goudreau, Sylvie Goulet, Teddy Halmos, Jean Rancourt
-
Publication number: 20110230465Abstract: Compounds of formula I: wherein X, R2, R3, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.Type: ApplicationFiled: September 16, 2010Publication date: September 22, 2011Applicant: BOEHRINGER INGLEHEIM INTERNATIONAL GMBHInventors: Timothy STAMMERS, Xavier BARBEAU, Pierre BEAULIEU, Megan BERTRAND-LAPERLE, Christian BROCHU, Paul J. EDWARDS, Pasquale FORGIONE, Cédrickx GODBOUT, Oliver HUCKE, Marc-André JOLY, Serge LANDRY, Olivier LEPAGE, Julie NAUD, Marc PESANT, Martin POIRIER, Maude POIRIER, Bounkham THAVONEKHAM
-
Publication number: 20110177030Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: April 1, 2011Publication date: July 21, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Josee BORDELEAU, Pasquale FORGIONE, Elise GHIRO, Vida GORYS, Nathalie GOUDREAU, Sylvie GOULET, Teddy HALMOS, Jean RANCOURT
-
Patent number: 7939667Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: GrantFiled: June 21, 2007Date of Patent: May 10, 2011Assignee: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Bailey, Punit Bhardwaj, Josee Bordeleau, Pasquale Forgione, Elise Ghiro, Vida Gorys, Nathalie Goudreau, Sylvie Goulet, Teddy Halmos, Jean Rancourt
-
Publication number: 20110021486Abstract: Compounds of formula I: wherein X, R2, R3, R3a, R3b, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.Type: ApplicationFiled: December 3, 2008Publication date: January 27, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Pierre L. Beaulieu, Pasquale Forgione, Alexandre Gagnon, Cedrickx Godbout, Marc-Andre Terrebonne, Montse Llinas-Brunet, Julie Naud, Martin Poirier, Jean Rancourt
-
Publication number: 20100286131Abstract: Compounds of formula I: wherein, R2, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.Type: ApplicationFiled: July 31, 2008Publication date: November 11, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Pierre L. Beaulieu, Pasquale Forgione, Alexandre Gagnon, Cedrickx Godbout, Julie Naud, Martin Poirier, Jean Rancourt, Timothy A. Stammers, Bounkham Thavonekham
-
Patent number: 7749961Abstract: Compounds of formula (I): wherein R1, R2, X, R3, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.Type: GrantFiled: January 19, 2005Date of Patent: July 6, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Bailey, Punit K. Bhardwaj, Francois Bilodeau, Pasquale Forgione, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Jean Rancourt
-
Patent number: 7705146Abstract: The invention relates to compounds of formula (I) wherein R?, R2, R3, R4, R5, R6, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I).Type: GrantFiled: June 22, 2005Date of Patent: April 27, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Murray D. Bailey, Punit Bhardwaj, Pasquale Forgione, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Montse Llinas-Brunet, Marc-Andre Poupart, Jean Rancourt
-
Publication number: 20100087382Abstract: Compounds of formula I: wherein R1, R2, R2a, R3, R4 and R5 are defined herein, are useful as inhibitors of the HCV NS3 protease.Type: ApplicationFiled: February 15, 2008Publication date: April 8, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Murray D. Bailey, Francois Bilodeau, Pasquale Forgione, Vida Gorys, Montse Llinas-Brunet, Julie Naud, Jeffrey O'Meara, Marc-Andre Poupart